Atherosclerotic diseases, including coronary artery disease (CAD) and myocardial infarction (MI), are the leading causes of death in the world. The genetic basis of CAD and MI, which are caused by multiple interacting endogenous and exogenous factors, has gained considerable interest in the last years as genome-wide association studies (GWASs) have identified many new susceptibility loci for CAD and MI, and the underlying genes provide new insights into the genetic architecture of these diseases. Here we summarize the recent findings from GWASs of atherosclerosis and discuss their functional and biological implications. We also discuss the different post-GWAS strategies that are currently used for refining the location of causal variants, understanding their role, and shedding light on molecular mechanisms explaining their association to CAD. We finally discuss potential clinical translations of GWAS findings for individual risk prediction, advanced clinical strategies, and personalized treatments. (Arterioscler Thromb Vasc Biol. 2012;32:170-181.)
O ver the last 5 years, genome-wide association studies (GWASs) have proved to be one of the most successful approaches by which to study the inherited basis of human diseases. Indeed, GWASs have identified hundreds of susceptibility genes for a large number of human conditions and quantitative traits. 1 The April 2011 release of the National Human Genome Institute's catalogue of published GWASs 2 contained 972 studies involving 4827 single-nucleotide polymorphisms (SNPs) with implications for human phenotypes. Such an impressive number of identified risk loci provides unprecedented new insights into the genetic architecture of various diseases, specifically if we compare this success story with the outcome of linkage and gene-candidate analyses in the past. However, only a small proportion of the overall genetic variance of the traits under investigation can be explained by the loci identified thus far. In addition, several associations localize within noncoding regions, challenging the interpretation of GWAS findings as causal genes, and molecular mechanisms are difficult to elucidate. This situation has created some skepticism about the utility of the GWAS approach and raised a debate about the so-called missing heritability. 3 Nevertheless, GWASs have already discovered some cellular pathways underlying the mechanisms of complex diseases. Lander provided examples of how this hypothesis-free approach may advance our understanding of pathophysiology. 4
GWASs for Atherosclerosis: Current Status
Several epidemiological, family, and twin studies have provided evidence of genetic roots in the development of coronary artery disease (CAD) and myocardial infarction (MI). First, positive family history of premature CAD is an established independent factor in prediction of clinical and subclinical disease risk. 5, 6 Second, approximately 50% of unexplained variation in cardiovascular risk can be attributed to genetic and environmental factors shared within a family. 7 Third, human single-gene mutations/variants underlying hypercholesterolemia have been identified (http://omim.org/entry/143890). Fourth, genetically modified animal models match human traits underlying CAD, such as familial hypercholesterolemia. 7 After several years of hypothesis-driven studies, 8 the GWAS approach has led to identification of several genomic regions putatively harboring CAD/MI susceptibility genes. 9, 10 Since the identification in 2007 of the 9p21.3 locus, [11] [12] [13] which is so far the most robustly replicated genetic signal for CAD around the world, 14 -16 several other loci have been identified by the Wellcome Trust Case Control Consortium 12, 17 ; the Ottawa Heart Study 11 ; German Myocardial Infarction Family Studies I, 12 II, 18 and III 19 ; deCode 20 ; and the Myocardial Infarction Genetics Consortium. 21 As of March 2011, 12 CAD loci had been identified (Table) . Since then, international efforts gathered GWAS cohorts for CAD and MI and carried out meta-analyses pooling hundreds of thousands of samples. Methodological CAD indicates coronary artery disease; MI, myocardial infarction; SNP, single-nucleotide polymorphism; ID, identification number; OR, odds ratio; eQTL, expression quantitative trait locus; LDL, low-density lipoprotein.
*Yes means that this locus is associated with a CAD risk factor or another pleiotropic effect, provided in Supplemental Table I . #eQTL effects are provided in Supplemental Table I .
Maouche and Schunkert GWASs for Atherosclerosis
progress in SNPs imputation 22 has allowed combining GWAS data sets from different array platforms, and performing large-scale analyses became feasible ( Figure 1 ). For CAD, the Coronary ARtery DIsease Genome-Wide Replication Meta-Analysis (CARDIoGRAM) consortium meta-analyzed 14 GWASs. 23, 24 CARDIoGRAM included 22 233 cases and 64 762 controls. The pooled analysis of this large sample replicated almost all previously identified common genetic variants and led to identification of 13 new loci with genome-wide significance (Table) . 24 Using a more focused study design, 2 additional loci were identified by members of this consortium. 19, 25 In addition to CARDIoGRAM, the International Consortium for Coronary Artery Diseases (C4D) 26 is another largescale meta-analysis of GWASs for CAD that was not limited to populations of European descent. C4D identified 3 additional new CAD/MI loci, which are listed in the Table. In the future, the pooling of samples from the 2 consortia and conducting even larger meta-analyses will probably allow identification of additional variants with small effects.
Considering these 18 loci identified by CARDIoGRAM 24 and the C4D, 26 the 12 previously identified genetic vari-ants, [11] [12] [13] [17] [18] [19] 21, 25, 27, 28 a new locus identified by Wang et al 29 in a Han Chinese population, and a variant in the DAB2IP gene identified by Gretarsdottir et al, 30 32 loci have now been established as having genome-wide significance (Table) .
CAD/MI loci identified by GWASs are characterized by the following proprieties:
1. Only a minority cover previously known CAD candidate genes. Rather, most loci harbor genes that have not been anticipated to be involved in the pathogenesis of atherosclerosis (Table) . An example for a new kid on the block is ADAMTS7, which appears to be involved in vascular smooth muscle cell migration and neointima formation in balloon-injured rat arteries, 31 vascular remodeling, 32 and the pathogenesis of arthritis. 33 2. Many loci are devoid of protein-coding genes. For some variants, the signal is even located in gene deserts. Herrington 7 suggests the existence of novel mechanisms for genotype-phenotype interactions that are still not yet understood. Indeed, the functional importance of gene deserts needs to be reevaluated given these findings. 3. With the exception of 7q32.2 (ZC3HC1) and 15q25 (MORF4L1), most loci show pleiotropic effects (ie, they 
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are associated with several phenotypes). The most pleiotropic loci are 11q23.3 (ZNF259-APOA5-APOA4-APOA1-APOC3) and 9p21.3 (CDKN2A/CDKN2B), which harbor 26 and 20 statistically significant associations with various phenotypes, respectively. A variant located Ϸ10 kb apart from the CAD/MI 9p21.3 susceptibility locus within a different haplotype block was found to be associated with type 2 diabetes. 34 -36 This risk locus was also found to be linked to abdominal aortic aneurysm and intracranial aneurysms, 37 initiation and progression of atherosclerosis, 38 stroke, 39 early onset of MI, 13 vascular dementia and Alzheimer disease, 40, 41 multiple cancer, 42 and premature death. In addition, Musunuru et al 43 have shown recently that the 9p21.3 locus is associated with platelet reactivity. Although these findings reveal that the complexity underlying the genomic basis of human disease is much greater than was initially thought, this pleiotropism may be very helpful in understanding some mechanisms shared among different diseases.
Most variants increase the probability of CAD and MI
only by a relatively small margin (Ϸ5%-20%, as shown in the Table) . The largest effects are observed for the risk alleles at 6q25.3 (LPA) and 9p21.3 (CDKN2A/ CDKN2B), which increase CAD risk by 51% and 29% per allele, respectively. 24 5. Almost all CAD and MI loci were identified in European populations. Although the 9p21.3 locus has been replicated in Asian and in African American populations, it is important to assess the generalizability of results for the CAD/MI susceptibility loci in other populations. 14 -16 6. Genes mapped to CAD/MI susceptibility loci show significant enrichment in lipoprotein metabolism, including genes such as LDLR, LPA, PCSK9, PEMT, and the nearest genes to the 11q23.3 locus (APOA1, APOA5, and APOC3). 7. Many CAD/MI-associated loci show expression quantitative trait locus (eQTL) effects, ie, they affect the expression level of genes either in cis (at the locus) or in trans (at remote locations) ( Table I , available online at http://atvb.ahajournals.org). 8. Figure 2 depicts a network for the CAD/MI-associated genes, constructed from STRING, a database for known and predicted protein-protein interactions. 45 Some nodes (genes) are connected including mainly genes involved in low-density lipoprotein (LDL) cholesterol and lipoprotein.
However, approximately 70% of the genes mapped to CAD/MI do not form any known network of proteinprotein interaction, cocitation in the literature, or coexpression network (nodes without connections on Figure 2 ). This suggests little functional interaction between these genes. However, enriching the network by genes interacting with each of the CAD/MI-associated genes may reveal many further indirect interactions (links) and mechanisms unifying these CAD genes into joint biological or cellular processes. The currently known subnetwork involves mainly genes involved in lipid and cholesterol metabolism ( Figure 2) .
Recently, the heterogeneity in the presentation of CAD raised the question whether distinct molecular mechanisms are involved in specific phenotypes, such as calcification or left main disease, and how this affects GWASs. 9, 46 Indeed, it appears that distinct coronary phenotypes, such as proximal stenosis or calcifications, carry a high heritability. 47 Several authors have investigated such subphenotypes of CAD, 25, 48, 49, 50 providing evidence that specific genetic predispositions promote the development of either coronary atherosclerosis or MI. However, the evidence for phenotype heterogeneity on the strength of association at previously identified CAD susceptibility loci is controversial. 48, 49, 50 Diemert and Schunkert 51 provide reflections on these aspects and a list of CAD phenotypes that might have distinct genetic etiology.
It is important to mention that in current GWASs of atherosclerosis, CAD and MI cases are analyzed together, as there is only limited evidence on the existence of genetic variants that could be associated only with MI or only with CAD.
CAD Loci, Risk Factors, and Disease Mechanisms
Once susceptibility genetic variants are identified by GWASs, the next logical question is how these variants affect disease risk. An obvious explanation may be by modification of traditional CAD risk factors. In CARDIoGRAM, we found only 3 variants associated with CAD risk factors in such quantitative dimension that the risk factor induction may explain the association with CAD (9q34.2 with total cholesterol and LDL; 10q24.32 with hypertension; and 11q23.3 with LDL, high-density lipoprotein, and total cholesterol). In this review, we report all associations found in GWAS catalogue for the 32 CAD loci. Supplemental Table II 9p21.3 locus is a common variant located Ϸ110 kb from 2 tumor suppressor genes, CDKN2A, CDKN2B, and 2 other genes, CDK2B-AS1 (ANRIL) and MTAP. Visel et al 54 have shown that deletion of the corresponding stretch of DNA in mice results in dysregulation of these genes. These authors, who also investigated possible in vivo effects of the risk allele on early stages of atherogenesis, did not find significant difference in fatty lesion formation. 54 It was suggested that the variant linked to CAD may downregulate CDKN2A and CDKN2B in mice, enhance vascular cell proliferation, and lead to excessive aortic smooth muscle cell proliferation. Holdt et al 55 57 have shown that in human vascular endothelial cells, interferon-␥ signaling activation and STAT1 binding at ECAD9 strongly affect the structure of chromatin and transcriptional regulation at the 9p21.3 locus. 57 It was also suggested that the 9p21.3 locus may influence CDKN2B-AS1 (ANRIL) regulation, which in turn is supposed to regulate CDKN2A and CDKN2B. This regulation may lead to increase in cellular proliferation and predispose to atherosclerosis 58, 59 although "the mystery of the 9p21.3 locus remains wide open." 52 In addition to 9p21.3, 1p13.3 (CELSR2-PSRC1-SORT1) has been the focus of intense functional experiments. This locus was initially identified to associate with CAD 12 before Teslovich et al 60 revealed that this locus is the strongest hit for LDL cholesterol out of 95 loci identified to associate with plasma lipid levels. Recently, Musunuru et al 61 demonstrated that the causal variant, which is associated with increase of expression levels of SORT1 in the liver, is located within a binding site for the transcription factor CCAAT/enhancer binding protein. It was suggested that SORT1 regulates hepatic lipoprotein production and that loss of expression of this gene induces hypercholesterolemia and atherosclerotic lesion formation. 62 By contrast, using knockout or overexpression of Sortilin 1 protein (SORT1) in mice, Kjolby et al 63 demonstrated that lower levels of SORT1 expression are associated to decreased level of LDL cholesterol and verylow-density lipoprotein secretion, which is opposite the conclusion of Musunuru et al, 61 who reported that lower levels of SORT1 mRNA are associated with increase of LDL Figure 2 . Interactions between genes mapped to coronary artery disease (CAD)/myocardial infarction (MI) susceptibility loci. The network, which was constructed from the STRING database, shows the interactions (links; protein-protein interactions, cocitation in the literature, coexpression) between genes (nodes) mapped to CAD/MI susceptibility loci. Lipase A, lysosomal acid, cholesterol esterase (LIPA) is involved in cholesterol metabolism, but no interaction was predicted for this gene with the remaining ones forming a subnetwork of CAD-associated genes involved in cholesterol metabolism.
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cholesterol and very-low-density lipoprotein secretion. Tall and Ai 64 have provided some elements to explain the opposite conclusions reported by Kjolby et al 63 and Musunuru et al. 61 The authors suggested that difference in experimental conditions and knockout models used by the 2 groups could explain their opposite findings. In addition, Dubé et al 65 have provided an interesting discussion on recent mechanistic studies of SORT1.
The MRAS locus (3q22.3) is known to play a role in neuronal differentiation. Moreover, recent data suggest a role in osteogenesis. It was also shown that MRAS is activated by bone morphogenetic protein-2 signaling and that it participates in the osteoblastic determination, differentiation, and transdifferentiation under p38 mitogen-activated protein kinase 1 and mitogen-activated protein kinase 8 also known as JNK regulation. Today, there is no known mechanism that could explain the functional effects of the CAD-causing variant.
ADAMTS-7 (15q25.1) has been suggested recently as novel therapeutic target for vascular restenosis and atherogenesis, as the enzyme affects the extracellular matrix of vascular smooth muscle cells. 66 Among the newly identified CAD/MI loci, SMG6 (17p13.3) is known to be involved in nonsense-mediated mRNA decay. 67 SRR, a gene in the region of the 17p13.3 risk locus, was previously shown to be associated with cardiac structure and function (aortic root size). 68 The RASD1 gene mapped to the 17p11.2 locus, which encodes a member of the Ras superfamily of small GTPases and is thought to play a role in dexamethasone-induced alterations in cell morphology, growth, and cell-extracellular matrix interactions. PPAP2B is known to actively hydrolyze extracellular lysophosphatidic acid and short-chain phosphatidic acid.
GIP is thought to induce insulin secretion 69 and to have significant effects on fatty acid metabolism. Using gastric inhibitory polypeptide receptor knockout mice, Yamada and Seino 70 provided evidence that gastric inhibitory polypeptide links overnutrition to obesity by acting on adipocytes.
No functional implications are known for TCF21 (6q23.2), which encodes a transcription factor of the basic helix-loop-helix family; HHIPL1 (14q32.2); ANKS1A (6p21.31); CYP17A1; CNNM2; NT5C2 (10q24.32); SNF8 and UBE2Z (17q21.32); ATP5G1 (17q21.32); SMCR3; PEMT; RAI1 (17p11.2); and ZC3HC1 (7q32.2). Several ongoing functional studies are likely to shed light on the direct or indirect mechanisms linking these loci to atherosclerosis and its complications.
A detailed discussion of the functional implications from the 12 CAD/MI-associated loci identified before the CAR-DIoGRAM initiative is given in a recent review by Sivapalaratnam et al. 71
Moving Beyond GWASs: Current Post-GWAS Strategies
The main challenges are now to (1) identify additional variants with moderate/small effects by performing further large scale metaanalyses, (2) identify the causative variants with strong effects and refine the architecture of identified loci, and (3) elucidate the molecular mechanisms underlying the association of the loci. In addition, it was suggested that the remaining heritability for CAD and MI may be explained by rare variants. 3 Ongoing efforts have been deployed to perform next-generation whole-genome or targeted-exome sequencing followed by large-scale genotyping (Figure 1 ). Translating GWAS findings to clinical application, ie, better prediction of CAD and MI and development of novel therapeutic strategies, 72 is the ultimate goal of genetics studies on CAD and MI, although this is still very challenging. Glazer emphasized that the finding of GWASs has been a revolution in biology rather than clinical medicine. 73 As pointed out by Lander, 4 one of the exciting results of GWASs is the evidence about the relevance of noncoding-regions in our genome. Glazer 73 discussed the necessity of follow-up on GWASs using multiple experimental methods and techniques and establishing collaborations between different scientific disciplines. He also emphasized the necessity of developing new bioinformatics methods integrating different genomic data to interpret GWAS findings.
Recently, several post-GWAS follow-up initiatives were initiated. The National Institutes of Health and National Cancer Institute launched the post-GWAS initiative (http:// grants.nih.gov/grants/guide/rfa-files/RFA-CA-09-002.html) and funded several transdisciplinary research projects with the aim of exploiting GWAS findings in cancer, which could provide the basis for expediting clinical translation of the findings. A similar initiative for CAD and related traits has been launched by the National Heart, Lung, and Blood Institute.
In term of methodology, several bioinformatics tools have been proposed these last few years to prioritize the identified variants for functional studies and predict of the functional consequences of each variant. 74
Fine-Mapping and Genotyping of Variants Identified by 1000 Genomes Project
It is important to keep in mind that variants identified by GWASs may be not causal but in strong linkage disequilibrium with the causal ones that are located in genes or the region nearby. Identifying causal variants is one the challenges in the post-GWAS era.
Fine-mapping is used for this purpose to derive more detailed information about the region identified by GWAS analysis, refine the location of each identified genetic variant, and eliminate false-positive signals. It uses deep sequencing of the surrounding region followed by genotyping of additional variants. However, this approach is time-consuming, expensive, and challenging, particularly when a locus of interest spans a large genomic region. However, custom-made arrays such as the MetaboChip (http://www.sph.umich.edu/csg/kang/MetaboChip/) may facilitate this process. Availability of arrays that allow combining GWASs and fine-mapping strategies, such as the Affymetrix Axiom genotyping arrays (http://www.affymetrix. com), will also help in identifying causal variants and refine findings of GWAS analysis.
It has been suggested that studying different ethnic groups with distinct haplotype patterns may help in the fine-mapping approach. In addition, it has been suggested that data from the 1000 Human Genome Project 75 may be used to investigate rare alleles without need for de novo sequencing. 73 Kim and Bhak 76 suggest that by typing the less frequent SNPs identified by the 1000 Genomes Project directly in the study samples, it will be possible to save the resequencing efforts in the follow-up studies.
Sanna et al 77 have used fine-mapping of 5 loci associated with LDL cholesterol by combining resequencing and genotyping variants provided by the 1000 Genomes Project. 75 The authors identified new functional variants and found that in 1 locus within the PCSK9 gene, the GWAS signal could be explained by a low-frequency SNP. Shea et al 78 used a similar approach and compared strategies for fine-mapping the association of common variants at the 9p21.3 locus with type 2 diabetes and MI but did not identify new variants with stronger associations than had already been discovered by the GWAS approach.
Use of eQTL Data to Interpret GWAS Findings
As most of the common variants identified by GWASs are located in noncoding regions, several authors have tried to make use of eQTL data to interpret GWAS findings. 24, 26 Specifically, variants located in a noncoding region may affect transcript abundance of genes either in cis or in trans or the splicing or stability of the transcript. Interestingly, some variants show an eQTL effect in different tissues, as demonstrated by Folkersen et al, 79 who examined the genetics of gene expression of recently identified loci in different tissues. Montgomery and Dermitzakis 80 nicely discussed how to integrate and interpret overlap between GWAS and eQTL studies. However, the joint interpretation is not evident at some loci, as illustrated by Supplemental Figure I for the MRAS locus (3q22.3). The initially identified variant (rs9818870) was found to affect in cis the expression level of MRAS in mammary artery tissue, in medial aortic tissues, and in adventitial aortic tissues. However, in CARDIoGRAM, the SNP showing the strongest effect was rs2306374 at the same locus, which was found to affect the expression of FAIM (3q22.3) in macrophages (Supplemental Figure I) , leaving open the question of whether MRAS or FAIM (or both) mediates the disease risk.
In Vivo and In Vitro Functional Experiments
Depending on the characteristics of the chromosomal region, different strategies are being used to elucidate the mechanisms by which genetic variants lead to diseases. 81 For nonsynonymous SNPs, specifically those mutations leading to changes in the coded protein, it will be feasible to functionally study both variants of the protein separately. Transfection experiments and promoter analyses could be used to study those variants located near regulatory elements. In addition, the recent progress in developing transgenic animal models will inform in vivo mechanistic studies. However, animal based studies carry several limitations mainly because of (1) their focus on single mutations, 82 (2) differences between human and animal physiology, (3) differences in the genetic structure and sequence of noncoding regions, and (4) the duration of experimental models, which are relatively short compared the development of pathological processes in humans. 81
Use of Pathway-Based and SNP-Set Enrichment Approaches
GWAS data are traditionally analyzed using single markers in a SNP-by-SNP approach. Only variants which reach genomewide statistical significance are being reported ignoring the joint interplay of multiple variants with moderate effects. Borrowing the strengths of gene-set enrichment analysis, developed initially for microarray gene expression data, recently SNP-set enrichment analysis (reviewed by Wang et al 83 ) has been adapted for GWAS analysis to identify additional diseases susceptibility variants by incorporating prior biological knowledge and focusing on groups of functionally related genes. Several research groups have reanalyzed their GWAS data sets using SNP-set enrichment analysis approaches (reviewed in Maouche et al, manuscript in preparation). For CAD, our group started recently within the CAR-DIoGRAM consortium a pathways analysis working group, which may identify CAD-related pathways and provide novel insights into the mechanisms of CAD and MI.
Systems Genetics Approaches and Network Medicine to Integrate Multiple Levels of Genomic Data
Systems genetics approaches, which integrate experimental and high-throughput genomics data and computational methods, will also play a growing role in merging all these data into the analysis and interpretation of GWAS findings. Recently, Nadeau and Dudley 84 nicely described this approach and discussed how it can be used for dissection of complex traits. Plaisier et al 85 have used an elegant systems genetics approach to show that FADS3 is a causal gene for familial combined hyperlipidemia (FCHL) and elevated triglycerides in Mexicans. The authors used network gene coexpression analysis and SNP data to assign a function to the genetic variants rs3737787 (1q21-q23) in USF1 gene, which was previously identified to be associated with FCHL. Network medicine 86 will play an important role in these analyses and is likely to advance our understanding of pathophysiological mechanisms of diseases with complex architecture, such as CAD and MI.
Epistasis and Gene-Environment Analysis
CAD and MI are complex diseases likely resulting from interaction of several genetic and environmental factors. Modeling gene-gene interactions and gene-environment interactions (epistasis) is important for the next step of analysis of GWAS data to understand how these factors interact with each other. Several studies have illustrated the importance of considering these interactions. Shirts et al 87 investigated gene-age interaction in high-density lipoprotein, LDL, and triglyceride levels and showed that the association between SORT1 and LDL is age dependent. However, because of the large number of studied markers, these interaction analyses are still very challenging. A review by Thomas nicely discusses the methodological aspects of gene-environment interactions in GWAS analysis. 88
Targeted Capture of Exome and Next-Generation Sequencing
The modest proportion of heritable risk for CAD and MI currently explained by genetic variants raised the question of
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Arterioscler Thromb Vasc Biol February 2012 the nature of missing heritability. One source may be rare variants (ie, variants with allelic frequency Ͻ1%), which are not represented on commercial SNP arrays. 73, 89 Nextgeneration sequencing and whole-exome capture have been demonstrated to be powerful approaches to studying mendelian diseases. 90 Applying these techniques to complex diseases, including CAD and MI, may lead to new insights into the genetics basis of these diseases. Although it is likely that next-generation sequencing will be a competitive alternative to next-generation GWASs, because of the costs, it is still not feasible to sequence a large number of individuals. Targeted sequencing (eg, all exons in the genome) is likely to be an intermediate accessible approach. To identify rare variants associated to cardiovascular disease, the National Heart, Lung, and Blood Institute has endorsed the GO Exome Sequencing Project (http://esp.gs.washington.edu/drupal), which is currently applying exome sequencing to well-phenotyped cardiovascular cohorts. This initiative will provide novel insights into whether the remaining heritability can be explained by rare variants not included in the first generation of GWASs.
Clinical Implications: Moving From Gene Discovery to Clinical Translation and Personalized Medicine
The ultimate goal of GWAS analysis and genomic medicine is to use the newly identified variants for advanced clinical strategies in management, prediction, and diagnostic and prognostic evaluation, as well as personalized therapy. However, in the context of complex disease, this is challenging for many reasons: (1) the identified variants explain only a limited fraction of disease risk; (2) currently identified risk alleles often show a high prevalence in the population such that virtually every subject carries a distinct set of multiple risk variants;
(3) precise molecular mechanisms, as well as gene-gene and gene-environment interactions (epistasis), still need to be discovered; and (4) GWAS findings are reported mainly on European populations, such that additional studies are required to identify new variants in other populations and to assess the generalizability of current GWAS results. Nevertheless, the whole field of atherosclerosis research has been vitalized by GWAS findings. Ongoing studies are likely to accelerate our understanding of the pathophysiological mechanisms of CAD, which will fertilize clinical translation and development of novel medical applications based on GWAS findings.
Conclusion
Studying atherosclerosis using a GWAS approach has yielded exciting new results and led to a rapid increase in the number of CAD susceptibility loci. The related genes have shed new light on the genetics architecture of CAD and MI and advanced our understanding of the relationships between genetic variability, disease risk factors, and pathophysiology of CAD and MI. The mechanisms underlying the association of these loci to CAD/MI remain largely unknown, and the effects are relatively small. Future challenges are (1) discovering further genetic variants through large-scale metaanalyses, pathway-based approaches, and high throughput se-quencing; (2) understanding the mechanisms linking the identified loci to CAD; and (3) translating the findings from CAD GWASs to novel and optimized therapeutic strategies for CAD risk prediction, monitoring, and treatment.
